When analyzing experiments and clinical data it is obvious that MBG and other Na/K-ATPase inhibitors hold promise to treat cancer and following anti-CS antibody treatment to PE patients we must expect a rise of Fli1 and be alert. This evidence concerns the gene FLI1 and cancer.